MT Newswires
United Therapeutics Insider Sold Shares Worth $3,821,130, According to a Recent SEC Filing
➖
AI Sentiment
Neutral
5/10
- Home
- UTHR
as of 12-08-2025 12:26pm EST
$478.72
$10.90
-2.23%
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Chart Type:
Time Range:
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | SILVER SPRING |
| Market Cap: | 20.3B | IPO Year: | 1999 |
| Target Price: | $495.08 | AVG Volume (30 days): | 424.3K |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 26.38 | EPS Growth: | 16.08 |
| 52 Week Low/High: | $266.98 - $492.62 | Next Earning Date: | 10-29-2025 |
| Revenue: | $3,128,400,000 | Revenue Growth: | 13.50% |
| Revenue Growth (this year): | 13.64% | Revenue Growth (next year): | 5.78% |
AI-Powered UTHR Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 18 hours ago
AI Recommendation
hold
Model Accuracy: 75.17%
75.17%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of United Therapeutics Corporation (UTHR)
ROTHBLATT MARTINE A
Sell
Chairperson & CEO
UTHR Dec 4, 2025
Avg Cost/Share
$479.76
Shares
4,000
Total Value
$1,920,043.09
Owned After
130
ROTHBLATT MARTINE A
Sell
Chairperson & CEO
UTHR Dec 3, 2025
Avg Cost/Share
$475.26
Shares
4,000
Total Value
$1,901,087.35
Owned After
130
ROTHBLATT MARTINE A
Sell
Chairperson & CEO
UTHR Dec 2, 2025
Avg Cost/Share
$480.86
Shares
4,000
Total Value
$1,925,142.67
Owned After
130
ROTHBLATT MARTINE A
Sell
Chairperson & CEO
UTHR Dec 1, 2025
Avg Cost/Share
$482.65
Shares
4,000
Total Value
$1,927,703.28
Owned After
130
EDGEMOND JAMES
Sell
CFO AND TREASURER
UTHR Dec 1, 2025
Avg Cost/Share
$481.07
Shares
21,000
Total Value
$10,079,695.58
Owned After
14,539
BENKOWITZ MICHAEL
Sell
PRESIDENT AND COO
UTHR Dec 1, 2025
Avg Cost/Share
$480.75
Shares
22,500
Total Value
$10,798,079.12
Owned After
2,263
ROTHBLATT MARTINE A
Sell
Chairperson & CEO
UTHR Nov 28, 2025
Avg Cost/Share
$487.90
Shares
4,000
Total Value
$1,950,550.24
Owned After
130
ROTHBLATT MARTINE A
Sell
Chairperson & CEO
UTHR Nov 26, 2025
Avg Cost/Share
$485.60
Shares
4,000
Total Value
$1,940,203.71
Owned After
130
MAHON PAUL A
Sell
EVP & GENERAL COUNSEL
UTHR Nov 26, 2025
Avg Cost/Share
$485.66
Shares
11,000
Total Value
$5,346,701.20
Owned After
43,331
ROTHBLATT MARTINE A
Sell
Chairperson & CEO
UTHR Nov 25, 2025
Avg Cost/Share
$476.86
Shares
4,000
Total Value
$1,901,305.04
Owned After
130
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Dec 4, 2025 | Sell | $479.76 | 4,000 | $1,920,043.09 | 130 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Dec 3, 2025 | Sell | $475.26 | 4,000 | $1,901,087.35 | 130 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Dec 2, 2025 | Sell | $480.86 | 4,000 | $1,925,142.67 | 130 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Dec 1, 2025 | Sell | $482.65 | 4,000 | $1,927,703.28 | 130 | |
| EDGEMOND JAMES | UTHR | CFO AND TREASURER | Dec 1, 2025 | Sell | $481.07 | 21,000 | $10,079,695.58 | 14,539 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Dec 1, 2025 | Sell | $480.75 | 22,500 | $10,798,079.12 | 2,263 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Nov 28, 2025 | Sell | $487.90 | 4,000 | $1,950,550.24 | 130 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Nov 26, 2025 | Sell | $485.60 | 4,000 | $1,940,203.71 | 130 | |
| MAHON PAUL A | UTHR | EVP & GENERAL COUNSEL | Nov 26, 2025 | Sell | $485.66 | 11,000 | $5,346,701.20 | 43,331 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Nov 25, 2025 | Sell | $476.86 | 4,000 | $1,901,305.04 | 130 |
Latest United Therapeutics Corporation News
UTHR Breaking Stock News: Dive into UTHR Ticker-Specific Updates for Smart Investing
Zacks
Catalyst (CPRX) Up 10% Since Last Earnings Report: Can It Continue?
📈
AI Sentiment
Highly Positive
8/10
Zacks
Corcept (CORT) Up 9.2% Since Last Earnings Report: Can It Continue?
➖
AI Sentiment
Neutral
4/10
FX Empire
Flurry of Bullish Inflows Sends United Therapeutics Higher
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
United Therapeutics Insider Sold Shares Worth $10,798,079, According to a Recent SEC Filing
➖
AI Sentiment
Neutral
5/10
Compare UTHR vs Leading Stocks
See how UTHR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "UTHR United Therapeutics Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.